摘要:
Cutting or grinding oil compositions which are suitable for use in a minimal quantity lubrication system in which a minimal quantity of an oil is supplied to the spot to be cut or ground of a work, together with air are reduced in stickiness and improved in lubricity.
摘要:
The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof. In the formula, R1 represents hydrogen atom, a halogen atom or cyano group; R2 and R3 are the same as or different from and each represents hydrogen atom, a C1-C4 lower alkyl group or a halogen atom; R4 represents hydrogen atom or a C1-C4 lower alkyl group; and the ring A represents cyanophenyl group, aminosulfonylphenyl group, aminopyridyl group, aminopyrimidyl group, a halopyridyl group or cyanothiophenyl group, provided that the case where all of R1, R2 and R3 are hydrogen atoms, where both R2 and R3 are hydrogen atoms or where the ring A is aminosulfonyl group and both R1 and R2 are halogen atoms is excluded. Further, when the ring A is cyanophenyl group, 2-amino-5-pyridyl group or a 2-halo-5-pyridyl group and R1 is cyano group or a halogen atom, at least one of R2 and R3 should not be a hydrogen atom.
摘要翻译:本发明创造出一种新型抗血管生成剂,并提供与常规抗肿瘤剂相比显示出高安全性的抗肿瘤剂,具有确定的作用并且能够长时间施用。 也就是说,其提供由下式(I)表示的吲哚化合物,其药理学上可接受的盐或其水合物。在式中,R 1表示氢原子,卤素原子或氰基; R 2和R 3各自表示氢原子,C 1 -C 4低级烷基或卤素原子; R 4表示氢原子或C 1 -C 4低级烷基; 并且环A表示氰基苯基,氨基磺酰基苯基,氨基吡啶基,氨基嘧啶基,卤代吡啶基或氰基噻吩基,条件是所有R 1,R 2和R 3均为氢原子的情况,其中 R 2和R 3都是氢原子,或者其中环A是氨基磺酰基并且R 1和R 2都是卤素原子。 此外,当环A为氰基苯基,2-氨基-5-吡啶基或2-卤代-5-吡啶基,R 1为氰基或卤素原子时,R 2和 R 3不应该是氢原子。
摘要:
The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them, wherein in the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR4bR5b)mb— (wherein R4b and R5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mb means an integer of 1 or 2); R1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.
摘要:
The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them, wherein in the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR4bR5b)mb— (wherein R4b and R5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mb means an integer of 1 or 2); R1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.
摘要:
The present invention relates to a pharmaceutical composition, a kit and a method for treating cancer, comprising a sulfonamide compound in combination with a substance having an EGF inhibitory activity.
摘要:
The present invention provides a novel bioactive substance having an antiangiogenic effect. The chemical compound represented by the formula (1) (wherein, R1 represents hydrogen atom, aldehyde group or a lower acyl group, R2 and R3 are the same as or different from each other and represent hydrogen atom or a lower alkoxy group or are combined to represent oxygen atom, R4 represents a lower alkyl group and R5 represents hydrogen atom or a lower alkyl group, provided that compounds in which R1 is aldehyde group, R2 and R3are different from each other and are hydrogen atom or methoxy group, R4 is ethyl group and R5 is hydrogen atom are excluded), a salt thereof or a hydrate thereof was isolated from the culture broth of genus Streptomyces and the structure thereof was analyzed.
摘要:
The present invention provides a method of minimal quantity lubrication cutting and grinding that can improve cutting and grinding properties and extend the life of tools. The minimal quantity lubrication cutting and grinding method of the present invention comprises supplying a compressed fluid containing 0.1 to 15 percent by volume of oxygen together with a cutting and grinding oil (particularly preferably an oil composition comprising an ester) to processing spots of a workpiece.
摘要:
The present invention provides a method of minimal quantity lubrication cutting and grinding that can improve cutting and grinding properties and extend the life of tools. The minimal quantity lubrication cutting and grinding method of the present invention comprises supplying a compressed fluid containing 0.1 to 15 percent by volume of oxygen together with a cutting and grinding oil (particularly preferably an oil composition comprising an ester) to processing spots of a workpiece.
摘要:
The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof: In the formula, R1 represents hydrogen atom, a halogen atom or cyano group; R2 and R3 are the same as or different from and each represents hydrogen atom, a C1˜C4 lower alkyl group or a halogen atom; R4 represents hydrogen atom or a C1˜C4 lower alkyl group; and the ring A represents cyanophenyl group, aminosulfonylphenyl group, aminopyridyl group, aminopyrimidyl group, a halopyridyl group or cyanothiophenyl group, provided that the case where all of R1, R2 and R3 are hydrogen atoms, where both R2 and R3 are hydrogen atoms or where the ring A is aminosulfonyl group and both R1 and R2 are halogen atoms is excluded. Further, when the ring A is cyanophenyl group, 2-amino-5-pyridyl group or a 2-halo-5-pyridyl group and R1 is cyano group or a halogen atom, at least one of R2 and R3 should not be a hydrogen atom.
摘要翻译:本发明创造出一种新型抗血管生成剂,并提供与常规抗肿瘤剂相比显示出高安全性的抗肿瘤剂,具有确定的作用并且能够长时间施用。 也就是说,其提供由下式(I)表示的吲哚化合物,其药理学上可接受的盐或水合物:在式中,R 1表示氢原子,卤素原子或氰基; R 2和R 3各自代表氢原子,C 1 -C 4低级烷基或卤素原子; R 4表示氢原子或C 1 -C 4低级烷基; 并且环A表示氰基苯基,氨基磺酰基苯基,氨基吡啶基,氨基嘧啶基,卤代吡啶基或氰基噻吩基,条件是所有R 1,R 2和R 3均为氢原子的情况,其中 R 2和R 3都是氢原子,或者其中环A是氨基磺酰基并且R 1和R 2都是卤素原子。 此外,当环A为氰基苯基,2-氨基-5-吡啶基或2-卤代-5-吡啶基,R 1为氰基或卤素原子时,R 2和 R 3不应该是氢原子。
摘要:
An impact absorption member is provided behind a bumper face, a lower stiffener is provided below this member and projects forward to sweep a leg portion of an object hitting against a front potion of a vehicle, and headlamp units are provided at both side portions of the bumper face. A lamp housing of the headlamp unit is supported at a vehicle-body member located in back of the lamp housing, a load absorption portion provided on the inside of and rearward from an edge of the bumper face to absorb an impact load is provided integrally at the lamp housing, and a load transmission portion to transmit the impact load inputted to the bumper face to the load absorption portion is provided at the bumper face.